GCIG-Intergroup-Horiz-rgb-300

October 15 – 21, 2021

to do or not to do: interval debulking in NACT patients Elise Kohn

Forums Topic Group 1 to do or not to do: interval debulking in NACT patients

Viewing 5 reply threads
  • Author
    Posts
    • #1110
      Nicoletta Colombo
      Participant

      At least patients should not be progressing on  NACT !!

       

    • #1114
      Dearbhaile O’Donnell
      Participant

      Agree.   Patients who do not have protocol time- mandated surgery will still be included in intention to treat analyses but the proportion is likely to be much more consistent across surgeons and centres

       

    • #1117
      Stephen Welch
      Participant

      I support the statement on recommendation for attempt at IDS.  As Ignace mentioned, depending on the timing of randomziation / nature of the trial, patients who do not go on to IDS should be excluded or evaluated as a separate group.

    • #1122
      Elise Kohn
      Participant

      Yes, Nicoletta–As long as everyone gets assessed at the same time, whether PDS or NACT, anyone with clear progression of disease would be off treatment by standard criteria.  That would leave IDS a clinical decision not a clinical trial decision.

    • #1210
      Asima Mukhopadhyay
      Participant

      What about patients who have IDS after receiving only  Platinum and not taxol for various reasons including poor performance status at presentation but improvement before surgery. They seem to have poor CRS/ observed chemotherapy response during surgery compared to C+T ( depending on biology) and  also the maximal effort given during surgery and may need consideration for stratification/ adjustment depending on the trial hypothesis?

    • #1228
      Elise Kohn
      Participant

      Great question, and something to consider when writing eligibility and stratification criteria for a switch maintenance study.

Viewing 5 reply threads
  • You must be logged in to reply to this topic.
X